|
Introduction of
Remoxipride
Remoxipride is a
substituted benzamide which was a promising antipsychotic
during clinical trials in the 1990's, but was removed due to
possible side effects.
Clinical trials of Remoxipride
Remoxipride is a selective D2 antagonist, with a relatively
low effective dosage and low incidence of side effects
relative to haloperidol. However, after its introduction in
Europe, its use was correlated with incidence of aplastic
anemia in as many as 1 in 10,000 cases, and it was taken off
the market until its relationship to this possible side effect
could be studied.
Disclaimer:
Information on this page is provided for general
information purposes. You should not make a clinical treatment
decision based on information contained in this page without
consulting other references including the package insert of
the drug, textbooks and where relevant, expert opinion. We
cannot be held responsible for any errors you make in
administering drugs mentioned on this page, nor for use of any
erroneous information contained on this page.
|